elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q38802191-91BFE131-19A2-40AA-97B7-9F74A466A14D
Q38802191-91BFE131-19A2-40AA-97B7-9F74A466A14D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38802191-91BFE131-19A2-40AA-97B7-9F74A466A14D
Recent development of targeted approaches for the treatment of breast cancer.
P2860
Q38802191-91BFE131-19A2-40AA-97B7-9F74A466A14D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38802191-91BFE131-19A2-40AA-97B7-9F74A466A14D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
dfe5fd32c0d7fa28de5bc50cc72c773f1171f91c
P2860
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.